Immuno-chemotherapy in Metastatic Renal Cell Carcinoma: Long-Term Results from the Rambam and Linn Medical Centers, Haifa, Israel

Gez, E.; Rubinov, R.; Gaitini, D.; Meretyk, Shimon; Best, Lael‐Anson; Mashiach, Tanya; Native, O.; Stein, Anthony S.; Kuten, Abraham

doi:10.1179/joc.2007.19.1.79

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gez et al [46] reported the long-term results of treatment with IL-2, IFN-a, 5-FU, and vinblastine in 62 patients with advanced RCC. RR was 40% (CR 18% and PR 22%) and the authors' conclusion was that nephrectomy, chemoimmunotherapy, and resection of residual disease should be recommended for patients with mRCC.…”

Section: Chemoimmunotherapymentioning

confidence: 98%

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

et al. 2013

View full text Add to dashboard Cite

The prognosis of patients affected by metastatic renal cell carcinoma (mRCC) has improved markedly with targeted therapies. Unfortunately, 20-25% of the patients are refractory to treatment at the first response assessment and most patients will acquire drug resistance during the treatment. Moreover, current data on the clinical activity of targeted agents in poor risk or non-clear-cell mRCC patients are inconclusive because of the absence of prospective trials. Therefore, there are still several patients in need of new therapeutic approaches to improve clinical outcomes. Kidney cancer is historically considered resistant to chemotherapy on the basis that the results of phase II trials have not always been promising. We carried out a systematic review of both monochemotherapy and polychemotherapy alone or combined with immunotherapy or targeted agents in mRCC to define the state of the art and to evaluate further clinical research fields. All retrospectives, phase I/dose finding, phase II and phase III studies on chemotherapy in mRCC, published in the literature from January 2003 to November 2012, with at least 20 patients enrolled, were evaluated. Although the results of clinical trials have often been disappointing, in selected cases of mRCC, chemotherapy may have a promising antitumor activity, particularly when there are sarcomatoid differentiation features, or in highly progressive disease where the combination of doxorubicine plus gemcitabine or capecitabine has yielded interesting results. Chemotherapy may play a role in mRCC, whereas targeted agents and immunotherapy have not yielded durable and satisfactory results; further studies are needed.

show abstract

Section: Chemoimmunotherapymentioning

confidence: 98%

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Registry data indicate that this practice may be widespread and further suggest that the efficacy of VEGF-TKIs as second-line therapy may be superior to that of mTOR antagonists [33]. To test this premise prospectively, an ongoing randomized trial is comparing sorafenib versus temsirolimus as second-line therapy in patients who have failed first-line sunitinib, with a primary endpoint of PFS [34]. The trial is anticipated to complete accrual by May 2011.…”

Section: Ongoing Comparative Trialsmentioning

confidence: 98%

Targeted therapies for renal cell carcinoma: understanding their impact on survival

Pal

Figlin

2010

Targ Oncol

View full text Add to dashboard Cite

Within the past 5 years, the United States Food and Drug Administration have approved six targeted agents for the treatment of metastatic renal cell carcinoma (mRCC). While this offers great potential to patients afflicted with this disease, oncologists are faced with the challenge of applying each agent in the appropriate clinical setting. Doing so requires an intricate understanding of the pivotal trials evaluating these agents. Herein, we have provided a detailed analysis of the study design employed in these trials. Use of appropriate comparator arms for targeted therapies (i.e., interferon-alpha or placebo) is addressed. Furthermore, we discuss the relative merits of using progression-free survival (PFS) or overall survival (OS) as a primary endpoint-importantly, the two endpoints may not be precisely correlated. Strategies to appropriately interpret OS in the context of post-study therapies and crossover designs are described. Ultimately, head-to-head trials comparing targeted therapies are necessary to resolve clinical equipoise. Several ongoing efforts juxtaposing the approved agents for mRCC are discussed.

show abstract

Immuno-chemotherapy in Metastatic Renal Cell Carcinoma: Long-Term Results from the Rambam and Linn Medical Centers, Haifa, Israel

Cited by 2 publications

References 19 publications

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

Targeted therapies for renal cell carcinoma: understanding their impact on survival

Contact Info

Product

Resources

About